A novel Cystic Fibrosis testing technology that features next-generation DNA sequencing platforms has been launched by Medical Diagnostic Laboratories (MDL).
The MDL Cystic Fibrosis Core Test is a CFTR gene sequence exam provided by MDL, is noninvasive and can test specimens through mouthwash samples, cervico-vaginal swabs, or blood samples from pregnant women. It uses breakthrough technology to provide a series of CF testing through high-accuracy genetic testing, and is able to screen the 23 major mutations recommended by the ACOG and the ACMG for the disease.
